Skip to main
VTVT

vTv Therapeutics (VTVT) Stock Forecast & Price Target

vTv Therapeutics (VTVT) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

vTv Therapeutics is a well-positioned company with a promising drug candidate in development, a strong cash balance, and potential partnerships and expansion opportunities. While there are risks involved in the clinical trials and market competition, the positive results seen in trials and the potential for future partnerships make vTv a favorable investment option for those with a long-term outlook.

Bears say

vTv Therapeutics is a late-stage biopharmaceutical company that focuses on developing oral, small-molecule drug candidates for diabetes and other chronic diseases. Despite the positive outlook for the FDA's prioritization of T1D and the potential for disease-modifying therapies, we have a negative outlook due to potential challenges in broad adoption of vTv's lead candidate cadisegliatin. Although it has shown promising results in reducing hypoglycemia and HbA1c, challenges such as regulatory hurdles, real-world adoption dynamics, and competition in the market may hinder its success. Additionally, our financial analysis indicates a potential peak revenue of $919M and a 12-month price target of $58, assuming a 60% probability of success.

vTv Therapeutics (VTVT) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of vTv Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About vTv Therapeutics (VTVT) Forecast

Analysts have given vTv Therapeutics (VTVT) a Strong Buy based on their latest research and market trends.

According to 5 analysts, vTv Therapeutics (VTVT) has a Strong Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

vTv Therapeutics (VTVT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.